Department of Health Outcomes and Pharmacy Practice, The University of Texas at Austin, College of Pharmacy, Austin, TX 78712-0127, USA.
Vaccine. 2012 Jun 22;30(30):4476-9. doi: 10.1016/j.vaccine.2012.04.074. Epub 2012 May 2.
Previous studies show that the tuberculosis and smallpox vaccine protect against melanoma because of sequence homologies they have with the melanoma antigen, HERV-K-MEL. The yellow fever 17D (YF 17D) vaccine is thought to have this property, so there is a possibility that the YF17D vaccine is able to protect against melanoma. This nested case-control study used the Defense Medical Surveillance System to assess the association between the YF17D vaccine and risk of malignant melanoma in active members of the United States military. Although point estimates hinted at a protective effect, none of the values reached a significant level. Therefore, this study concluded that in the ten year period following vaccination there is no association between the yellow fever 17D vaccine and risk of malignant melanoma in active members of the US armed forces.
先前的研究表明，由于结核和天花疫苗与黑色素瘤抗原 HERV-K-MEL 具有序列同源性，因此它们可以预防黑色素瘤。黄热病 17D（YF 17D）疫苗被认为具有这种特性，因此有可能 YF17D 疫苗能够预防黑色素瘤。这项巢式病例对照研究利用国防医疗监测系统评估了 YF17D 疫苗与美国现役军人恶性黑色素瘤风险之间的关联。尽管点估计暗示了保护作用，但没有一个数值达到显著水平。因此，本研究得出结论，在接种疫苗后的十年内，黄热病 17D 疫苗与美国武装部队现役人员恶性黑色素瘤的风险之间没有关联。
